标题
The Optimal Duration of Adjuvant Chemotherapy in Colon Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 9, Pages 2509
出版商
MDPI AG
发表日期
2020-09-03
DOI
10.3390/cancers12092509
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
- (2020) Fausto Petrelli et al. JAMA Oncology
- Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
- (2020) F. Pagès et al. ANNALS OF ONCOLOGY
- Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
- (2020) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer
- (2020) Hannah A. Blair Molecular Diagnosis & Therapy
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
- (2019) Timothy Iveson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
- (2019) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
- (2019) J Souglakos et al. ANNALS OF ONCOLOGY
- Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer
- (2019) Takayuki Yoshino et al. JAMA Oncology
- 525OACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
- (2019) T Yoshino et al. ANNALS OF ONCOLOGY
- LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
- (2019) Timothy Iveson et al. HEALTH TECHNOLOGY ASSESSMENT
- FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial
- (2018) Alberto Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
- (2018) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Colon Cancer, Version 2.2018
- (2018) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- (2015) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
- (2014) M. Yoshida et al. ANNALS OF ONCOLOGY
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) R. Labianca et al. ANNALS OF ONCOLOGY
- Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
- (2012) I Mochizuki et al. BRITISH JOURNAL OF CANCER
- Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
- (2011) C. Twelves et al. ANNALS OF ONCOLOGY
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started